GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Understanding PPARgamma signaling in melanoma brain metastasis

$399,971
Qing Chen · Wistar Institute · R01 · FY2022 · CA

Stroma-penetrating nanomedicine to improve treatment for pancreatic cancer

$399,970
Katherine Marie Eichinger · Duo Oncology Inc · R41 · FY2024 · CA

Notch function in postnatal intestinal and mesenteric lymphatics

$399,961
Carrie J. Shawber · Columbia University Health Sciences · R01 · FY2019 · DK

CD3 bispecific for the treatment of ROR2-positive NSCLC

$399,955
Jean-Loup Romet-Lemonne · Traverse Biotech Ii Inc · R43 · FY2023 · CA

Project 3

$399,955
Hideki Furuya · Methodist Hospital Research Institute · U54 · FY2025 · CA

Precision lung cancer therapy design through multiplexed adapter measurement

$399,937
Aaron Samuel Meyer · University Of California Los Angeles · U01 · FY2019 · CA

Discovering Fusobacterium nucleatum's Impact on Breast Cancer Progression and Treatment with POx Micelle Technology

$399,829
Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R21 · FY2025 · CA

New models for interrogating the impact of sex chromosomes and sex hormones on glioblastoma

$399,829
Joseph Edward Ippolito · Washington University · R21 · FY2025 · CA

Human specific STING agonists for the treatment of cancer

$399,812
Glen N Barber · Stinginn, Llc · R41 · FY2023 · CA

Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell death

$399,806
Yoon Yeo · Purdue University · R01 · FY2022 · CA

Transcriptional Regulation of Dormancy and Emergence in Breast Cancer

$399,784
Partha Roy · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Informatics Tools To Analyze And Model Whole Slide Image Data At The Single Cell Level

$399,771
Guanghua Xiao · Ut Southwestern Medical Center · U01 · FY2022 · CA

Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma

$399,752
Deepak Saxena · Periomics Care, Llc · R41 · FY2020 · CA

Engineering a potent locally-acting interleukin 12-expressing synthetic self-replicating mRNA to augment responses to anti-PD-1 therapy in neoadjuvant triple negative breast cancer

$399,725
Tasuku Kitada · Strand Therapeutics Inc · R43 · FY2021 · CA

Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles

$399,669
Elizabeth E Sweeney · Immunoblue, Llc · R41 · FY2024 · CA

Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy

$399,658
Nicole J. Shirkey-Son · Luminary Therapeutics, Inc. · R43 · FY2021 · CA

Phase II trial of ADXS11-001 vaccine for HPV-related oropharyngeal cancer

$399,622
Andrew Sikora · Baylor College Of Medicine · R01 · FY2015 · FD

Development of Lasso Peptides as Potent Endothelin Receptor B Antagonists for Immuno-oncology

$399,609
Mark J Burk · Lassogen, Inc. · R43 · FY2021 · CA

Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer

$399,586
Fatemeh Sadat Majedi · Symphony Biosciences, Inc. · R44 · FY2023 · CA

(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer

$399,582
Raymond Nelson Dubois · Arizona State University-Tempe Campus · R01 · FY2015 · CA

Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer

$399,580
Jacki Kornbluth · Vanquish Bio Llc · R41 · FY2022 · CA

Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors

$399,571
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2023 · CA

Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors

$399,569
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2022 · CA

Platelet Serine/Threonine Phosphatases in Cancer Pathophysiology

$399,554
K. Vinod Vijayan · Baylor College Of Medicine · R01 · FY2024 · CA

Abnormal Stem Cell Trafficking in IM

$399,509
Ronald Hoffman · Icahn School Of Medicine At Mount Sinai · P01 · FY2011 · CA